Literature DB >> 8327692

Hyperechoic renal cell carcinomas: increase in detection at US.

H P Forman1, W D Middleton, G L Melson, B L McClennan.   

Abstract

Recent reports have indicated that hyperechoic renal cell carcinomas (RCCAs) are more frequent among small cancers and that small cancers are being detected more frequently. To determine whether these trends have resulted in a change in the frequency of detection of hyperechoic RCCA and, in particular, in the frequency of RCCA mimicking angiomyolipomas (AMLs), the sonographic features of 90 pathologically proved RCCAs in 82 patients were retrospectively reviewed and correlated with tumor size. Tumor echogenicity was compared with that of normal renal parenchyma and classified as hypoechoic, isoechoic, slightly hyperechoic, or markedly hyperechoic. Thirty-one tumors were 3 cm in diameter or less, and 59 were larger than 3 cm. Ten (32%) of the tumors 3 cm in diameter or less were markedly hyperechoic and mimicked AMLs, whereas only one (2%) of the tumors larger than 3 cm had this appearance (P < .001). Eleven of the 90 tumors (12%) were markedly hyperechoic. Twenty-four (77%) of the small tumors were either slightly or markedly hyperechoic, compared with 19 (32%) of the larger tumors (P < .001). Because of the increased detection of small RCCAs in recent years, the number of hyperechoic cancers and the number of cancers mimicking AMLs have increased.

Entities:  

Mesh:

Year:  1993        PMID: 8327692     DOI: 10.1148/radiology.188.2.8327692

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

1.  Point Shear Wave Elastography Using Machine Learning to Differentiate Renal Cell Carcinoma and Angiomyolipoma.

Authors:  Hersh Sagreiya; Alireza Akhbardeh; Dandan Li; Rosa Sigrist; Benjamin I Chung; Geoffrey A Sonn; Lu Tian; Daniel L Rubin; Jürgen K Willmann
Journal:  Ultrasound Med Biol       Date:  2019-05-25       Impact factor: 2.998

2.  Evaluation of renal masses with contrast-enhanced ultrasound: initial experience.

Authors:  Scott Gerst; Lucy E Hann; Duan Li; Mithat Gonen; Satish Tickoo; Michael J Sohn; Paul Russo
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

3.  Angiomyolipoma being surgically excised for presumed kidney carcinoma.

Authors:  Weibin Hou; He Xiao; Guanghua Liu; Zhigang Ji
Journal:  Int Urol Nephrol       Date:  2015-05-05       Impact factor: 2.370

4.  Diagnostic efficacy of contrast-enhanced ultrasound for small renal masses.

Authors:  Tae Hoon Oh; Young Hwan Lee; Ill Young Seo
Journal:  Korean J Urol       Date:  2014-09-05

Review 5.  Renal Cell Carcinoma Ablation: Preprocedural, Intraprocedural, and Postprocedural Imaging.

Authors:  Winston B Joe; Jessica G Zarzour; Andrew J Gunn
Journal:  Radiol Imaging Cancer       Date:  2019-11-29

Review 6.  Imaging of Solid Renal Masses.

Authors:  Fernando U Kay; Ivan Pedrosa
Journal:  Radiol Clin North Am       Date:  2016-12-12       Impact factor: 2.303

Review 7.  Imaging of Solid Renal Masses.

Authors:  Fernando U Kay; Ivan Pedrosa
Journal:  Urol Clin North Am       Date:  2018-06-15       Impact factor: 2.241

8.  The role of quantitative measurement by acoustic radiation force impulse imaging in differentiating benign renal lesions from malignant renal tumours.

Authors:  Cemil Göya; Mansur Daggulli; Cihad Hamidi; Alpaslan Yavuz; Salih Hattapoglu; Mehmet Guli Cetincakmak; Memik Teke
Journal:  Radiol Med       Date:  2014-08-06       Impact factor: 3.469

9.  The application of ultrasound contrast agents in the characterization of renal tumors.

Authors:  Salvatore Siracusano; Emilio Quaia; Michele Bertolotto; Stefano Ciciliato; Anna Tiberio; Emanuele Belgrano
Journal:  World J Urol       Date:  2004-08-06       Impact factor: 4.226

10.  Predictive value of contrast-enhanced ultrasound combined with conventional ultrasound in solid renal parenchymal lesions.

Authors:  Yingyu Cai; Fan Li; Zhaojun Li; Xin Li; Chunxiao Li; Zhen Xia; Lianfang Du; Rong Wu
Journal:  Br J Radiol       Date:  2021-07-28       Impact factor: 3.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.